Navigation Links
The Pill Comes Under the Spotlight

FDA advisors are planning to review existing birth control pills this week. This decision follows results from clinical studies that show the incidence of pregnancies to// have increased by twice over the last 10 years, while the subjects were on the pill.

Improper use, inferior products and other reasons are considered, as causes for this observation and the panel will discuss whether more stringent guidelines will be needed for safety and efficacy.

The Pill is the most popular method of the birth control in the U.S., accounting for more than 30 percent of all birth control use, according to the Mayo Clinic, while tubal sterilization, or the surgical blocking of a woman's fallopian tubes, is the second-most popular at 27 percent. Male condoms are next, at 18 percent.

Some 19 percent of all American women aged 15 to 44 use The Pill, according to the Centers for Disease Control. But many men and women don't use birth control at all, or they use it without success.

The outcome of these meetings could affect the 13 million-plus women and girls who take birth control pills in America, and the estimated $4 billion market for birth control drugs, dominated by Barr, Watson, Johnson and Johnson and Wyeth pharmaceuticals.

Pills approved in the 1960's allowed less than one pregnancy per 100 women taking the pill for a year. Newer pills allow over two pregnancies in a similar group of women.

Experts say this may be partly because new pills have fewer hormones that could lead to dangerous blood clots and heart disease.

The topics to be discussed by the FDA panel include: Clinical trial design issues, contraceptive efficacy and risk or benefit assessment cycle control (scheduled and unscheduled bleeding and spotting) and other measures of product acceptability to the user, translation of clinical trial findings of efficacy and safety into "real world" effectiveness and safety, extended dosing regimens, ph ase 4 commitments by applicants for further investigation, generally of uncommon but serious safety issues and role and impact of labeling for communication of clinical trial findings including product efficacy, risk, and other benefits.

FDA officials hope to use this information to create a guidance document for the clinical investigation of hormonal contraceptives.
ANN
'"/>




Related medicine news :

1. Lung Cancer: Nutritional Intervention Comes To The Rescue
2. Girl Comes Out Of Irreversible Coma
3. Poultry Owner Comes Up With Novel Idea To Boost Up Chicken Sales
4. Nurses Outsmart Surgeons When It Comes Safety And Team Wok
5. NICE Comes Under Attack
6. Yoga and Meditation Comes in Aid of Iraqis to Rid of Trauma
7. After Ecstasy Comes the Pain… WARNING
8. Ban On Trans Fats Comes Into Effect From July 1
9. Hospital Performance Measures May Not Make Much Difference When It Comes to Mortality
10. Sleeping Sickness Comes to India
11. Prolactin Comes to the Aid of MS Sufferers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... ... ... The Radiology Business Management Association (RBMA) is pleased to announce ... process has been in place since the RBMA was founded in 1968 with all ... Jim Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive officer for ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... exposed to more adverse experiences than children in the general population. That’s because ... abuse, neglect or other family challenges. While no fault of their own, youth ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... of America (UCAOA) and College of Urgent Care Medicine will host industry leaders ... sessions and speakers will help those in the industry adapt to the issues ...
(Date:4/28/2017)... ... April 28, 2017 , ... People are starting to accept ... a hearing aid doesn’t have the stigma it had when great-grandpa wore his hearing ... Greater Boston, in a NALA North American Speaker Series (NASS) segment. “He ...
(Date:4/28/2017)... ... ... Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, has published a ... does not. Yisrayl says with so many titles and names for the Creator, it’s ... with a little Scripture, backed with a lot of research, the truth is undeniable. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... PLANO, Texas , April 20, 2017  Vivify ... via mobile devices, has been awarded a very significant ... care via EMRs to continual care via digital health. ... of key intellectual property and further secures Vivify,s position ... Vivify, launched in 2009, was the first company to ...
(Date:4/20/2017)... 2017  CVS Pharmacy, the retail division of ... store design to enhance the retail customer experience ... products and expanded beauty selections paired with informational ... new offerings. Together with its innovative digital programs, ... customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
Breaking Medicine Technology: